Photo from wikipedia
Recombinant human IL-2 (rhIL-2) is now rarely used to treat patients with cancer because it too often causes severe toxicities. In this issue, Nirschl and colleagues report the development and… Click to show full abstract
Recombinant human IL-2 (rhIL-2) is now rarely used to treat patients with cancer because it too often causes severe toxicities. In this issue, Nirschl and colleagues report the development and preclinical characterization of an engineered IL-2 prodrug called WTX-124 that activates in the tumor microenvironment and has minimal systemic toxicity. It will be intriguing to watch the translation of this approach to the clinic. See related article by Nirschl et al. (5).
Keywords:
cancer gains;
protein therapeutic;
function spot;
therapeutic cancer;
gains function;
cancer
Journal Title: Cancer immunology research
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer immunology research
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!